Document text
Principal Investigator: Kathleen Engelman
Organization: UNIV OF MASSACHUSETTS MED SCH WORCESTER
Fiscal Year: 2020
Award: $323,571
Funding agency: NIH Office of the Director
Project Summary
The Nonhuman Primate Reagent Resource (NHPRR) develops recombinant biological materials to support
research with animal models of human diseases. In our parent P40 award, we produce and distribute
approximately 400g of recombinant protein reagents per year. Therefore, we have the tools, expertise, and
infrastructure to manufacture recombinant reagents and distribute them widely. Very recently, coronavirus
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID) was declared a pandemic,
which prompted the development of new animal models. Unfortunately, the potentially infectious nature of
COVID samples has precluded the exchange of reference serum samples among centers developing monkey
models of COVID. Thus, our plan is to create safe recombinant reference macaque immunoglobulin standards
to facilitate the development and validation of reliable assays for the detection of pathogenic coronaviruses and
antiviral antibodies in NHP animal models of COVID. Specifically, this supplement will fund the generation of the
following reagents: recombinant coronavirus-reactive rhesus monoclonal IgGs (Aim 1) and NHP serum reference
standards (Aim 2). These macaque reference antibody reagents will improve the performance and comparability
of antibody-based assays for NHP models by facilitating serum assay development, proficiency training, and
inter-laboratory performance comparisons at the NPRCs (see letters of support).
Terms: <2019 novel coronavirus><2019-nCoV><7S Gamma Globulin><Address><Amino Acids><Animal Disease Models><Animal Model><Animal Models and Related Studies><Animals><Antibodies><Assay><Award><Bioassay><Biocompatible Materials><Biologic Assays><Biological><Biological Assay><Biomaterials><Biomedical Research><Blood Serum><COVID><California><Cell Body><Cells><Clinical Treatment Moab><CoV disease><Containment><Coronaviridae><Coronavirus><Detection><Development><Disease><Disorder><ELISA><Engineering><Enzyme-Linked Immunosorbent Assay><Funding><Generations><Goals><Grant><Human><IgG><Image><Immune><Immune Globulins><Immunes><Immunity><Immunoglobulin G><Immunoglobulins><Infection><Infectious Agent><Infrastructure><Institution><Investigators><Laboratories><Lateral><Letters><M mulatta><M. mulatta><Macaca><Macaca mulatta><Macaque><Measurement><Methods><Modeling><Modern Man><Monkeys><Monoclonal Antibodies><Nature><Parents><Pathogenicity><Pathology><Patients><Performance><Preparation><Primates><Primates Mammals><Public Health><Reagent><Recombinant Antibody><Recombinant Proteins><Recombinants><Reference Standards><Reproducibility><Research><Research Infrastructure><Research Institute><Research Personnel><Research Resources><Research Support><Researchers><Resources><Rhesus><Rhesus Macaque><Rhesus Monkey><SARS Virus><SARS corona virus><SARS coronavirus><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV-2><SARS-CoV2><SARS-Related Coronavirus><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Saliva><Sampling><Serologic><Serological><Serum><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe acute respiratory syndrome coronavirus 2><Standardization><Strategic Planning><Testing><Texas><Time><Training><Validation><Viral Antibodies><Washington><Wuhan coronavirus><aminoacid><anti-viral antibody><antiviral antibody><assay development><base><biological material><corona virus><corona virus disease><coronavirus disease><developmental><diagnostic assay><human disease><human model><imaging><improved><infectious organism><mAbs><member><model of animal><model of human><model organism><non-human primate><nonhuman primate><pandemic><pandemic disease><programs><reagent standard><screening><severe acute respiratory syndrome-CoV><tool><work group><working group>